Division of Maternal Foetal Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Department of Obstetrics and Gynaecology, Addis Ababa University College of Health Sciences, Addis Ababa, Ethiopia.
Lancet Infect Dis. 2023 Apr;23(4):e151-e159. doi: 10.1016/S1473-3099(22)00687-9. Epub 2022 Nov 11.
HIV infection is a clinically significant public health disease and contributes to increased risk of maternal and fetal morbidity and mortality. HIV pregnancy studies use outcome measures as metrics to show how people with HIV feel, function, or survive. These endpoints are crucial for tracking the evolution of HIV illness over time, assessing the effectiveness of antiretroviral therapy (ART), and comparing outcomes across studies. Although the need for ideal outcome measures is widely acknowledged, selecting acceptable outcome measures for these HIV pregnancy studies can be challenging. We discuss the many outcome measures that have been implemented over time to assess HIV in pregnancy studies, their benefits, and drawbacks. Finally, we offer suggestions for improving the reporting of outcome measures in HIV in pregnancy studies. Medical professionals can best care for pregnant women living with HIV receiving ART by having a thorough understanding of these outcome metrics.
HIV 感染是一种具有临床意义的公共卫生疾病，会增加母婴发病率和死亡率。HIV 妊娠研究使用结局指标来衡量 HIV 感染者的感觉、功能或生存情况。这些终点对于跟踪 HIV 疾病随时间的演变、评估抗逆转录病毒疗法 (ART) 的有效性以及比较研究结果至关重要。尽管广泛认识到需要理想的结局指标，但为这些 HIV 妊娠研究选择可接受的结局指标可能具有挑战性。我们讨论了随着时间的推移实施的许多用于评估妊娠期间 HIV 的结局指标，以及它们的优点和缺点。最后，我们为改善 HIV 妊娠研究中结局指标的报告提出了建议。通过全面了解这些结局指标，医疗专业人员可以更好地为接受 ART 的 HIV 阳性孕妇提供护理。
